Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation

  • Report highlights key progress and achievements across three pillars: access to medicines, R&D innovation, and product quality and patient safety
  • 430,000 patients have been treated with Samsung Bioepis’ biosimilars across 40 countries in 2023
  • In 10 countries, our biosimilars have created social impact worth approximately 2.5 trillion KRW (1.9 billion USD) in 2023
  • The company reaffirms its commitment to achieving Net Zero by 2050 as part of the global effort to tackle climate change; company’s first report on Task Force on Climate-Related Financial Disclosures (TCFD) to be released in second half of 2024

INCHEON, Korea, June 25, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today issued its 2024 sustainability report, underscoring its progress toward building more sustainable and socially responsible practices in access to medicines, R&D innovation, and product quality and patient safety.

“In pursuit of our vision ‘Passion for Health’, we ensure that our environmental, social and governance responsibilities are systematically managed. This year’s sustainability report reflects our ongoing efforts to deliver positive social impact to patients while maintaining transparency and accountability in all aspects of our operations,” said Christopher Hansung Ko, President and Chief Executive Officer at Samsung Bioepis. “Through our operations, we make sure that we’re making positive contribution to the communities we serve and also fostering long-term value for all of our stakeholders including patients, communities and governments.”

The annual report provides a comprehensive overview of Samsung Bioepis’ performance and management of the company’s commitment to sustainability, and key highlights of the report are as follows:

1) Access to Medicines: In 2023 alone, Samsung Bioepis’ seven biosimilar medicines have been used to treat approximately 430,000 patients across 40 countries. 2023 witnessed biosimilar launches across several therapeutic areas, including adalimumab biosimilar launch in the United States and ophthalmology and hematology biosimilar launches in Europe. Based on assessment across 10 countries, our biosimilars have been estimated to create 2.5 trillion KRW (1.9 billion USD) social impact by helping healthcare systems achieve cost savings and by improving patients and caregivers quality of life and work productivity.i

2) R&D Innovation: We are continuing to optimize our biosimilar development platform through Quality by Design (QbD), Tollgate Systems, and Failure Modes and Effects Analysis (FMEA). We are able to develop biosimilars more effectively at a faster speed through higher productivity of cell line development, optimization of scale-up system, automation of analysis methods, digitalization of data management, and computerized modeling for process development. In addition, we are expanding R&D into antibody drug conjugates (ADC) and cell and gene therapy (CGT) by collaborating with biotech companies for research and development of drugs to explore new business growth opportunities.

3) Product Quality and Patient Safety: We have implemented a very stringent quality management system which allows us to detect potential quality risks in advance and manage them effectively in a timely manner. This has allowed us to provide biosimilar medicines that are quality-assured from cell line development to commercial manufacturing. As a result, we have not received any warning letter from regulatory agencies, for 35 inspections which were conducted throughout 2021-2023.

In addition, Samsung Bioepis received two ISO certifications: ISO 27001 (Information Security Management System) and ISO 45001 (Occupational Safety & Health Management System) in August 2023, underscoring the company’s commitment to providing healthy and safe workplace environment and ensuring information security. Since 2022, together with Samsung Biologics, Samsung Bioepis is committed to achieving Net Zero by 2050, as part of the global effort to tackle climate change. At the heart of the commitment is achieving net zero carbon emissions (Scope 1 & Scope 2) by converting our direct and indirect energy sources to renewable energy in mid-to-long term.

The company’s report is formulated in the Global Reporting Initiative (GRI) Standards and details activities and achievements that are aligned with the Sustainability Accounting Standards Board (SASB) Standards. Samsung Bioepis’ detailed ESG performance can be found in the full report: https://bit.ly/3L0i7CM

Assessing our ESG Impact

Samsung Bioepis has been conducting a double materiality assessment to assess and prioritize 10 material issues: 1) product responsibility and safety, 2) access to medicines, 3) supply chain ESG risk management, 4) R&D and product innovation, 5) ethics and compliance management, 6) climate change, 7) governance, 8) human resources and talent management, 9) product lifecycle quality management, and 10) ethics for clinical trial and animal testing. These issues are assessed based on both financial and impact materiality, and are being managed based on key metrics and targets set for each issue. We also engage with our stakeholders – customers, employees, suppliers, vendors, investors, shareholders, academic institutions, local communities, governments, media, and trade associations – and incorporate their feedback when assessing the material issues and our ESG performance.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – X, LinkedIn.

MEDIA CONTACT
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com

_____________________________

i 10 countries are the United States (US), Germany, France, Italy, Spain, United Kingdom (UK), Republic of Korea, Canada, Australia, and Brazil.


Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation

THỦ THUẬT HAY

Samsung ra mắt bộ nhớ mới có tốc độ cao nhất UFS 4.0

Samsung hiện đang tham dự sự kiện Flash Memory Summit 2022 để giới thiệu những sản phẩm mới nhất của mình trong lĩnh vực hệ điều hành. Một trong số đó là thông báo bắt đầu sản xuất flash modules dựa trên tiêu chuẩn UFS

Trải nghiệm Animoji trên iPhone, iPad cũ không có Face ID

Animoji nổi tiếng của Apple (và Memoji) chỉ khả dụng trên iPhone và iPad có Face ID. Nhưng bạn có thể trải nghiệm tương tự trên các thiết bị cũ bằng những ứng dụng trong bài viết.

Parallels Desktop 14 mang tới những điều tuyệt vời gì khi chạy Windows trên Mac

Gần đây, Parallels đã phát hành bản 14 của phần mềm máy ảo hàng đầu - Parallels Desktop. Nó là một trong những cách tốt & dễ nhất để chạy Windows trên Mac. Phần mềm cho phép bạn chạy phiên bản mới và tuyệt nhất của

Bỏ qua quảng cáo của link rút gọn và đến trực tiếp link gốc trên Chrome, Cốc Cốc và Firefox

Một số trang web download hiện nay thường dùng link rút gọn thông qua các dịch vụ như Fshare, adf.ly, short.am, ouo.io,LinkShrink.net... Mà đặc điểm chung của những link này là chứa rất nhiều quảng cáo, nhấn vào sẽ

Hướng dẫn kiểm tra lỗi RAM trên Windows đơn giản nhất

Nếu máy tính của bạn thường xuyên bị khởi động lại, hoặc gặp màn hình xanh,... thì nhiều khả năng RAM bị lỗi chính là nguyên nhân của tất cả các vấn đề này. Hôm nay, TCN sẽ hướng dẫn các bạn cách kiểm tra và check lỗi

ĐÁNH GIÁ NHANH

Galaxy A03s – Thủ lĩnh hiệu năng pin khủng 5000mAh, camera chất lượng giá 3 triệu

Với mức giá siêu hời chỉ hơn 3 triệu, Galaxy A03s xứng tầm là thủ lĩnh hiệu năng trong phân khúc thỏa mãn người dùng mùa giãn cách này với nhiều tác vụ gaming, lướt web, quay chụp ngay tại nhà. Sau 3 tuần sử dụng, cùng

Đánh giá chi tiết xe Toyota Wigo 2018

Dòng xe Hatchback cỡ nhỏ đô thị Toyota Wigo 2018 được Toyota Việt Nam phân phối chính hãng với hai lựa chọn phiên bản số sàn và số tự động, trang bị động cơ xăng 1.2L hướng đến nhóm khách hàng trẻ đô thị. Giá bán xe

Đánh giá chi tiết Nokia 2 giá 2.4 triệu đồng

Máy được đóng hộp đơn giản nhưng đầy đủ phụ kiện bao gồm củ sạc 5V-2A, cáp microUSB, tai nghe, sách HDSD.